WO2012170827A3 - Pyrazolopyrimidines and related heterocycles as ck2 inhibitors - Google Patents

Pyrazolopyrimidines and related heterocycles as ck2 inhibitors Download PDF

Info

Publication number
WO2012170827A3
WO2012170827A3 PCT/US2012/041567 US2012041567W WO2012170827A3 WO 2012170827 A3 WO2012170827 A3 WO 2012170827A3 US 2012041567 W US2012041567 W US 2012041567W WO 2012170827 A3 WO2012170827 A3 WO 2012170827A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pyrazolopyrimidines
inhibitors
activity
related heterocycles
Prior art date
Application number
PCT/US2012/041567
Other languages
French (fr)
Other versions
WO2012170827A2 (en
Inventor
Mustapha Haddach
Joe A. Tran
Fabrice Pierre
Collin F. Regan
Nicholas B. Raffaele
Suchitra Ravula
David M. Ryckman
Original Assignee
Senhwa Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences, Inc. filed Critical Senhwa Biosciences, Inc.
Publication of WO2012170827A2 publication Critical patent/WO2012170827A2/en
Publication of WO2012170827A3 publication Critical patent/WO2012170827A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:
PCT/US2012/041567 2011-06-08 2012-06-08 Pyrazolopyrimidines and related heterocycles as ck2 inhibitors WO2012170827A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494660P 2011-06-08 2011-06-08
US61/494,660 2011-06-08

Publications (2)

Publication Number Publication Date
WO2012170827A2 WO2012170827A2 (en) 2012-12-13
WO2012170827A3 true WO2012170827A3 (en) 2014-05-01

Family

ID=47296763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/041567 WO2012170827A2 (en) 2011-06-08 2012-06-08 Pyrazolopyrimidines and related heterocycles as ck2 inhibitors

Country Status (1)

Country Link
WO (1) WO2012170827A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845754B2 (en) 2018-10-30 2023-12-19 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SG11201505347VA (en) 2013-01-15 2015-08-28 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
EP3142652B1 (en) 2014-05-14 2021-08-25 The Regents of the University of Colorado, a body corporate Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
CN107801397B (en) * 2015-02-13 2021-07-30 达纳－法伯癌症研究所公司 LRRK2 inhibitors and methods of making and using the same
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (en) 2015-09-09 2017-11-29 Incyte Corp SALTS OF A PIM QUINASA INHIBITOR
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017070137A1 (en) * 2015-10-20 2017-04-27 Bristol-Myers Squibb Company Combination of ck2 inhibitors and immune checkpoint modulators for cancer treatment
CN109562111B (en) * 2016-06-24 2023-04-04 北极星药业股份有限公司 CK2 inhibitors, compositions and methods thereof
CN113444046B (en) * 2016-07-20 2023-10-27 纳莹(上海)生物科技有限公司 Fluorescent probe and preparation method and application thereof
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135581A1 (en) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as kinase inhibitors
WO2011031979A1 (en) * 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Pharmaceutically useful heterocycle-substituted lactams
WO2011068667A1 (en) * 2009-12-04 2011-06-09 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135581A1 (en) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as kinase inhibitors
WO2011031979A1 (en) * 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Pharmaceutically useful heterocycle-substituted lactams
WO2011068667A1 (en) * 2009-12-04 2011-06-09 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845754B2 (en) 2018-10-30 2023-12-19 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Also Published As

Publication number Publication date
WO2012170827A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012170827A3 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2011012369A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors.
IN2012DN03112A (en)
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2017006366A (en) 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors.
WO2015004533A3 (en) Novel substituted bicyclic compounds as bromodomain inhibitors
WO2015015318A3 (en) Novel quinazolinones as bromodomain inhibitors
EA201591753A1 (en) 3-PYRIMIDIN-4-ILOXAZOLIDIN-2-ONE AS MUTANT IDH INHIBITORS
BR112012013508A2 (en) pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2014005928A (en) Heterocyclic inhibitors of glutaminase.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
SG11201400616YA (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
WO2014080290A3 (en) Cyclic amines as bromodomain inhibitors
EA201391626A1 (en) COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-STIMULATED CANCER TYPES
WO2014080291A3 (en) Biaryl derivatives as bromodomain inhibitors
WO2013163190A8 (en) Dna-pk inhibitors
SG179163A1 (en) Novel tricyclic protein kinase modulators
JOP20120246B1 (en) COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS
EA201890768A3 (en) TREATMENT OF MALIGNANT TUMOR INHIBITORS TOR-KINASE
WO2012135113A3 (en) Cyclopropylamines as lsd1 inhibitors
MX342509B (en) Substituted indazole derivatives active as kinase inhibitors.
MX2014002486A (en) Compounds and compositions as pdgfr kinase inhibitors.
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12795997

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12795997

Country of ref document: EP

Kind code of ref document: A2